medigraphic.com

2006, Número S2

Rev Mex Anest 2006; 29 (S2)


Guías para el Diagnóstico, Prevención y Tratamiento de la Enfermedad Tromboembólica Venosa

Villagómez AJ, Carrillo ER, Alcántar LE, Avelar F, Ayala LEA, Bautista BEG, Cabrera RA, Cantú BC, Enríquez VE, Espinosa LF, Fuentes TS, García CJ, Gutiérrez FP, Halabe CJ, Hernández HJ, Quintana GS, Ochoa CFJ, Majluf CA, Martínez MC, Martínez ZR, Nellen HH, Palomar LH, Ramírez A, Jerjes-Sánchez DC, Sauri AJCA, Sobrerilla-Calvo P, Tanus HJ, Vázquez DIM, Xibillé FD, Zaragoza DJC

Idioma: Español
Referencias bibliográficas: 129
Paginas: 303-334
Archivo PDF: 196.70 Kb.


RESUMEN

En México tenemos la necesidad de desarrollar y difundir consensos, lineamientos y guías para diversos aspectos de la medicina, en la cual, por la gran disparidad de criterios o por la simple desinformación, se siguen conductas diagnósticas y terapéuticas distintas en cada institución, hospital, servicio e, inclusive, entre cada clínico. Esta falta de uniformidad impide obtener datos epidemiológicos vitales, desarrollar investigación clínica coherente, planificar los recursos óptimamente y cumplir con el objetivo más importante: disminuir la morbilidad y mortalidad en nuestro país. La enfermedad tromboembólica venosa es una de las principales causas de morbilidad y mortalidad hospitalaria en el mundo. Aunque desconocemos los datos exactos en nuestro país, estamos seguros que una mayor uniformidad de criterios entre las especialidades involucradas en su prevención, diagnóstico y tratamiento nos aclarará más el panorama de esta entidad y contribuirá a un abordaje más racional e interdisciplinario, el cual salvará vidas, mejorará la calidad de vida de los pacientes, ahorrará recursos y elevará el nivel de conocimiento de esta entidad tan frecuente. Lo anterior es una justificación suficiente para el esfuerzo dirigido por el Colegio de Medicina Interna de México, el cual, mediante el apoyo de otras Sociedades Médicas involucradas y del trabajo colegiado de expertos y especialistas en el tema, se dio a la tarea de desarrollar estas guías mediante una metodología de consenso de diversos equipos de trabajo. Estos equipos, reunidos ya en una sesión de trabajo plenario, llevaron sus criterios a la uniformidad y al acuerdo, de tal manera que la bibliografía está revisada y actualizada para tratar de adaptarla a nuestra realidad y circunstancia nacional.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Geerts WH, Heit JA, Claget GP, Pineo GF, Colwell CW, Anderson FA, Wheeler HB. Prevention of venous thromboembolism. Chest 2001;119:132S–175S.

  2. Spyropoulus AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest 2005;118:958-969.

  3. Carson JS, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J, Hobbins TE. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240-1245.

  4. Sigler L, Romero T, Meillón LA, Gutiérrez L, Aguirre GJ, Esparza C. Tromboembolia pulmonar en un período de 10 años. Rev Med IMSS 1996;34:7-11.

  5. Sandoval ZJ, Martínez GML, Gómez A, Palomar A, Pulido T, Zevallos M. PAC Cardio-1. Tromboembolia pulmonar aguda. Sociedad Mexicana de Cardiología. Editorial Intersistemas, México, DF. 1998:7-9.

  6. Monreal M, Kakkar AK, Capriani JA, Barba R, Uresandi F, Valle R, Suárez C, for the RIETE investigators. Is the natural history of venous thromboembolism different in surgery and non-surgery patients? Findings from the RIETE registry. Blood 2003;102:112b.

  7. Alikhan R, Cohen AT, Combe S, Samama M, Desjardins L, Eldor A, Jenbon C. Risk factors for venous thromboembolism in hospitalized patients with acute medical illnes: Analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-968.

  8. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-450.

  9. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients. Are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203-205.

  10. Marik PE, Andrews L, Maini B. The incidence of deep venous thrombosis in ICU patients. Chest 1997;111:661-664.

  11. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Garden G. Deep venous thrombosis in medical-surgery critically ill patients: Prevalence, incidence and risk factors. Crit Care Med 2005;33:1565-1571.

  12. Geerts WH, Pineo GF, Heit JA, Bergquist D, Lassen MR, Colwell CW, Ray SG. Prevention of venous thromboembolism. Chest 2004;126:338S-400S.

  13. Zucker MB. Platelet agglutination and vasoconstriction as factors in spontaneous hemostasis in normal, thrombocytopenic, heparinized, and hypothrombinemic rats. Am J Phyisol 1947;148:275-278.

  14. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature (Lond) 1990;343:757-760.

  15. Slack SM, Cui Y, Turitto VT. The effects of flow on blood coagulation and thrombosis. Thromb Haemost 1993;70:129-134.

  16. Furie B, Furie C. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806.

  17. Blombäck B, Blombäck M. The molecular structure of fibrinogen. Ann NY Acad Sci 1972;202:77-97.

  18. Stenflo J, Fernlund P, Egan W, Roespstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974;71:2730-1974.

  19. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988;57:915-956.

  20. Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618-623.

  21. Yamamoto M, Nakagaki T, Kisiel W. Tissue factor-dependent autoactivation of human blood coagulation factor VII. J Biol Chem 1992;267:19089-19094.

  22. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977;74:5260-5264.

  23. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991;30:10363-10370.

  24. Majluf-Cruz A, DeLa Cadena R. El sistema de contacto: su papel en la hemostasia y su relación con otros sistemas biológicos. En: Martínez-Murillo C, Quintana-González S. Manual de hemostasia y trombosis. Editorial Prado, 1996.

  25. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990;76:731–736.

  26. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993;7:308-316.

  27. Loskutoff DJ, Sawdey M, Mimuro J, Keeton M, Schneiderman J, Lang I, Schleef R. Type 1 plasminogen activator inhibitor. Prog Hemostasis Thromb 1989;9:87–115.

  28. Marder VJ, Shulman NR, Carroll, WR. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969;244:2111-2119.

  29. Sappino AP, Huarte J, Vassalli JD, Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 1991;87:962–970.

  30. Rosenberg RD, Rosenberg SJ. Natural anticoagulant mechanisms. J Clin Invest 1984;74:1-6.

  31. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264:4743-4746.

  32. Lobato-Mendizabal E, Majluf-Cruz A. Thrombophilia, thromboembolism and the use of the unfractionated and low-molecular-weight heparins. Rev Invest Clin 2000;52:529-545.

  33. Rocha Hernando E. Estados hipercoagulables. Blood 1997;42:452.

  34. Martínez-Murillo C, Quintana-González S, Ambriz-Fernández R, Hernández PM. El problema trombótico. Hematología 2000;1:17-20.

  35. Shafer A. The hypercoagulable states. Ann Intern Med 1985;102:814-828.

  36. Majluf-Cruz A. Mecanismos hemostáticos. En: Fundamentos de Hematología, GJ Ruiz Argüelles. Ed. Med. Panamericana 1998:264-288.

  37. Nygaard K, Brown G. Essential thrombophilia. Report of five cases. Arch Int Med 1937;59:82-106.

  38. Scazziota A, Altman R. El mecanismo de la hemostasia normal. Rev Iberoamer Trom Hemost 1994;7:95-109.

  39. Angle E. Overview on fibrinolysis: Plasminogen activation pathways on fibrin and cell surfaces. Chem Physc Lipids 1994;67/68:353-362.

  40. Girolami A, Simioni P, Zanardi S. The hereditary thrombosis. Rev Iberoamer Trom Hemost 1993;6:113-117.

  41. Schroeder W, Koessling M, Wulff K, Wehnert M, Hermann FH. World distribution of factor V Leiden mutation. Lancet 1996;347:58-59.

  42. Malm J, Laurell M, Nilsson IM, Dahlback B. Thromboembolic disease: Critical evaluation of laboratory investigation. Thromb Haemost 1992;68:7-15.

  43. Miron MJ, Perrier A, Bounameaux H. Clinical assessment of suspected deep vein thrombosis: Comparison between a score and empirical assessment. J Intern Med 2000;247:249-254.

  44. Hull RD. Revisiting the past strengthens the present: An evidence-based medicine approach for the diagnosis of deep venous thrombosis. Ann Internal Med 2005;142:583-585.

  45. Anand S, Wells P. Does this patient have deep vein thrombosis? JAMA 1998;279:1094-1099.

  46. Douketis JD. Use of a clinical prediction score in patients with suspected deep venous thrombosis: Two steps forward, one step back? Ann Intern Med 2005;143:140-142.

  47. Rathbun SW, Whitsett TL, Raskob GE. Negative d-Dimer result to exclude recurrent deep venous thrombosis: A management trial. Ann Intern Med 2004;141:839-845.

  48. Jennersjo CM, Fagerberg IH, Karlander SG, Lindahl TL. Normal D-dimer concentration is a common finding in symptomatic outpatients with distal deep vein thrombosis. Blood Coag Fibrinol 2005;16:517-523.

  49. Jerjes–Sánchez C, Elizalde GJ, Sandoval J, Gutiérrez–Fajardo P, Seoane GLM, Ramírez–Rivera A, Bautista E y cols. Guías de la Sociedad Mexicana de Cardiología para la estratificación, diagnóstico y tratamiento de la tromboembolia pulmonar aguda. Arch Cardiol Mex 2004;74:S548–S555.

  50. Task Force on Pulmonary Embolism, European Society Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000;21:1301-1336.

  51. A Collaborative Study by the PIOPED Investigators: Value of the ventilation/perfusion scan in acute pulmonary embolism: Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990;263:2753-2759.

  52. Goldhaber SZ. Pulmonary embolism. Lancet 2004;363:295-305.

  53. McConnel MV, Solomon SD, Rayan ME. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996;78:469-473.

  54. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis. JAMA 1990;263:2753-2759.

  55. Ghaye B, Remy J, Remy-Jardin M. Non-traumatic thoracic emergencies: CT diagnosis of acute pulmonary embolism: the first 10 years. Eur Radiol 2002;12:1886-1905.

  56. Remy-Jardin M, Remy J, Deschildre F, Artaud D, Beregi JP, Hossein-Foucher C, Marchandise X, and Duhamel A. Diagnosis of pulmonary embolism with spiral CT: Comparison with pulmonary angiography and scintigraphy. Radiology 1996;200:699-706.

  57. Van Rossum AB, Pattynama PM, Mallens WM, Hermans J, Heijerman HG. Can helical CT replace scintigraphy in the diagnostic process in suspected pulmonary embolism? A retrospective-prospective cohort study focusing on total diagnostic yield. Eur Radiol 1998;8:90-96.

  58. Schoepf UJ, Das M, Schneider AC, Anderson A, Wood SA, Costello P. Computer aided detection (CAD) of segmental and subsegmental pulmonary emboli on 1-mm multidetector-row CT (MDCT) studies. Radiology 2002;225(P):384.

  59. Remy-Jardin M, Tillie-Leblond I, Szapiro D, Ghaye B, Cotte L, MastoraI, Delannoy V, Remy J. CT angiography of pulmonary embolism in patients with underlying respiratory disease: Impact of multislice CT on image quality and negative predictive value. Eur Radiol 2002;12:1971-1978.

  60. Qanadli SD, El Hajjamm M, Vieillard-Baron A, Joseph T. Mesurolle B, Oliva VL, Barre O, Bruckert F, Dubourg O. Lacombe P New CT index to quantify arterial obstruction in pulmonary embolism: Comparison with angiographic index and echocardiography. Am J Roentgenol 2001;176:1415-1420.

  61. Majluf-Cruz A, García-Chávez J, Martínez-Murillo C. Enfermedad tromboembólica venosa. 1ª Edición, 2005. Editorial Garmarte.

  62. Mammen EF. Current development in antithrombotic therapy. Sem Thromb Haemost 2004;6:605-607.

  63. Walenga J, Hoppensteadt D. Monitoring the new antithrombotic drugs. Sem Thromb Haemost 2004;6:683-695.

  64. Weitz J, Hirsh J, Samama M. New anticoagulant drugs. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:265S–286S.

  65. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000;160:181–8.

  66. Warkentin TE. Heparin-induced thrombocitopenia: Pathogenesis and management. Br J Haematol 2003;121:535-555.

  67. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S.

  68. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004;140:867-873.

  69. Hainer J, Per Sprogel P, Lindenstroem E. An example based on the low-molecular weight heparin, tinzaparin. Sem Thromb Haemost 2004;30:3-9.

  70. Anderson JC. Advances in anticoagulation therapy: The role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery. Sem Thromb Haemost 2004;6:609-618.

  71. Martínez-Murillo C. Hacia un consenso nacional de tromboembolismo venoso. Gac Med Mex 2000;136:133-137.

  72. Kaboli P, Henderson MC, White RH. DVT prophylaxis and anticoagulation in the surgical patient. Clin Med N Am 2003;87:77-110.

  73. Sanderink GJ, Liboux AL. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308-318.

  74. Carrillo ER, Carrillo CJR. Profilaxis de la enfermedad tromboembólica venosa en cirugía y anestesiología. Editorial Alfil, México DF, 2005.

  75. Huber O, Bournameaux H, Bourst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. Arch Surg 1992;127:310-313.

  76. Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Hass S, Hull R, Kalodiki E, Myers K, Samama M, Sasahara A. Cardiovascular Disease Educational and Research Trust and the International Union of Angiology. Prevention of venous thromboembolism. International Consensus Statement. Int Angiol 1997;16:3-38.

  77. Holger J, Schünemann H, Munger H, Broker S, O¨Donnell M, Crowther M, Cook D, Guyat G. Methodology for guideline development for the Seventh American College of Chest Physicians conference on antithrombotic and thrombolytic therapy. Chest 2004;126:174S-178S.

  78. Wilson WA, Ghavari AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R. International consensus statement on preliminary classification criteria for definitive antiphospolipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-1311.

  79. Petri M. Epidemiology of the antiphospolipid syndrome. J Autoimmun 2000;15:145-151.

  80. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortín P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura Y, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133-1138.

  81. Danilenko-Dixon DR, Heit JA, Watkins T, Silverstein MD, Yawn B, Petterson TM, Lohse CM, O’Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or the postpartum period: a population-based case-control study. Am J Obstet Gynecol 2001;184:104-110.

  82. Dilley A, Austin H, El-Jamil mM, Hooper W, Barnhart E, Evatt BL, Sullivan PS, Ellingsen D, Patterson-Barnett A, Eller D, Randall H, Philipp C. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 2000;183:1271-7.

  83. Carter C. Oral contraceptives and thrombosis. Curr Opin Pulm Med 2000;6:296-300.

  84. Miller J, Benjamin KS, Heidi DN. Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for de US preventive services Task Force. Ann Intern Med 2002;136:680-690.

  85. Asell JE. Air travel venous thromboembolism–is the evidence in? N Engl J Med 2001;345:828-829.

  86. Cesarone MR, Belcaro G, Nicolardes AN. Venous thrombosis from air travel: The LONFLIT3 study. Prevention with aspirin vs. low-molecular-weight heparin (LMWH)- in high-risk subjects: A randomized trial. Angiology 2002;53:1-6.

  87. Lee AYY. Management of thrombosis in cancer: Primary prevention and secondary prophylaxis. Br J Haematol 2004;128: 291-302.

  88. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–1850.

  89. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New Engl J Med 2003;349:146-153.

  90. Evidence Based Guidelines Group American Burn Association. Deep venous thrombosis prophylaxis in burns. J Burn Care Rehabil 2001;22:67S-69S.

  91. Hankey GJ. Low-molecular weight heparins or heparinoids versus standard non fractioned heparin for acute ischaemic stroke. Cochrane Corner. Stroke 2005;36:2045-2046.

  92. Ferro JM, Canhao P, Stam J, Bousser JS, Barinagarrementeria F, for the ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664-670.

  93. Stawicki SP, Grossman MD, Cipolla J, Hoff WS, Hoey BA, Wainwright G, Reed JF. Deep venous thrombosis and pulmonary embolism in trauma patients: an overstatement of the problem. Am Surg 2005;71:387-392.

  94. Hirsh J, Hull RD. Venous Thromboembolism: Natural history, diagnosis, and management. CRC Press, Boca Raton, Florida, 1988.

  95. Bergqvist D. Postoperative thromboembolism: Frequency, aethiology, prophylaxis. Springer Verlag, New York, 1983.

  96. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001;38:12-19.

  97. Gensini GF, Prisco D, Falciani M, Comeglio M, Colella A. Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost 1997;23:55-67.

  98. Drucker EA, Rivitz SM, Shepard JA, Boiselle PM, Trotman-Dickenson B, Welch TJ, Maus TP, Miller SW, Kaufman JA, Waltman AC, McLoud TC, Athanasoulis CA. Acute pulmonary embolism: assessment of helical CT for diagnosis. Radiology 1998;209:235-241.

  99. Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-520.

  100. Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 1982;2:463-467.

  101. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G16991A (Leiden) and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele specific PCR. Thromb Haemost 1999;81:733-738.

  102. Keenan CR, White RH. Age as a risk factor for venous thromboembolism after major surgery. Curr Op Pulmon Med 2005;11:398-402.

  103. Christen Y, Wutschert R, Weimer D, de Moerloose P, Kruithof EK, Bounameaux H. Effects of intermittent pneumatic compression on venous haemodynamics and fibrinolytic activity. Blood Coagul Fibrinolysis 1997;8:185-190.

  104. Few JW, Marcus JR, Placik OJ. Deep vein thrombosis prophylaxis in the moderate-to-high-risk patient undergoing lower extremity liposuction. Plast Reconstr Surg 1999;104:309-310.

  105. Comerota AJ, Chouhan V, Harda RN, Sun L, Hosking J, Veermansunemi R, Comerota AJ Jr, Schlappy D, Rao AK. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226:306-313.

  106. Oates-Whitehead RM, D’Angelo A, Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. The Cochrane library. The Cochrane Collaboration; 2005.

  107. Baykal C, Al A, Demirtas E, Anyhan A. Comparison of enoxaparin and standard heparin in gynecologic oncologic surgery: a randomized prospective double-blind clinical study. Eur J Gynaecol Oncol 2001;22:127-130.

  108. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1998;208:227-240.

  109. Mismetti P, Laporte S, Darmon J-Y, Buchmuller A and Decousus H. Mismetti P: meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-930.

  110. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Moigne-Amrani AL, Dietrich-Neto F. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980.

  111. Society of American Gastrointestinal Endoscopic Surgeons: Global statement on deep venous thrombosis prophylaxis during laparoscopic surgery. www.sages.org/sg_pub_c.html

  112. Mohr DN, Silversteins MD, Heit JA, Petterson TM, O´Fallon WM, Melton LJ. The venous stasis syndrome after venous thrombosis or pulmonary embolism; a population based study 112. Mayo Clinic Proceedings 2006;75:1249-56.

  113. Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes Surg 2003;13:819-25.

  114. Rosenthal D, Willons ED, Lai KM, Bikk A, Henderson VJ. Retrievable inferior vena cava filters: Initial clinical results. Ann Vasc Surg 2006; 20:157-165.

  115. Sauerland S, Angrisani L, Belachew M, Chevallier JM, Favretti F, Finer N, Fingerhut A, García CM, Guisado JM, Mittermair M, Morino M, Msika M, Rubino F, Tachinno R, Weiner R, Neugebauer EA. Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc 2005;19:200-221.

  116. Gonzalez QH, Tishler DS, Plata-Munoz JJ, Bondora A, Vickers SM, Leath T, Clements RH. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. Surg Endosc 2004;18:1082-1084.

  117. Choudhary AM, Graver D, Nelson A, et al. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg 2000;10:7-14.

  118. Bounameaux H, Didier D, Polat O. Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy. Thromb Res 1997;86:271-273.

  119. Samuelsson E, Hagg S. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet Gynecol Scand 2004;83:674-681.

  120. Kakkar VV, Stringer MD. Prophylaxis of venous thromboembolism. World J Surg 1990;14:670-678.

  121. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 2003;124:386-392.

  122. Macouillard G, Castagnera L. Claviere JP, et al. Comparative efficacy of two dosages of a low molecular weight heparin for prevention of deep venous thrombosis in spinal surgery. Thromb Haemost 1995;73:979.

  123. Norwood SH, McAuley CE, Berne JD, Vallina VL, Kerns DB, Grahm TW, McLarty JW. A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients. J Am Coll Surg 2001;192(2):161-7.

  124. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, McL Black P. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 122:1933-1937.

  125. Clagett GP, Anderson FA, Heit J, Knudson HM, Lieberman JR, Merli GJ, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108:312S-334S.

  126. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996;156:1645-1649.

  127. Ansell J, Hirsch J, Poller L, Bussey H, Jacobson A, Hylec E. The pharmacology and management of vitamin K antagonist. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;136:204S–233S.

  128. Westling A, Bergqvist D, Bostrom A, Karacagil S, Gustavsson S. Incidence of deep venous thrombosis in patients undergoing obesity surgery. World J Surg 2002;26:470-473.

  129. Khansanaria S, Dennis JW, Veldenz HC, Butcher JL, Hartlan L. Prophylactic Greenfield filter placement in selected high risk trauma patients. J Vascular Surg 1995;22:231-5; discussion 235.




2020     |     www.medigraphic.com